Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoreline in male patients with prostate cancer
NL-OMON42816Phase 3Active, not recruiting
- Sponsor
- Novalon S.A.
- Start
- Oct 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of goserelin in prostate cancer (PCa) and prostate adenocarcinoma, sponsored by Novalon S.A. Primary endpoint: Pharmacodynamic responder rate. Started Oct 2015; status: active, not recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on NL-OMON42816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42816.